Details of the Drug

General Information of Drug (ID: DMWEJ0C)

• Drug Name: FGF401
• Synonyms: Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 1/2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 506.6
  Logarithm of the Partition Coefficient (xlogp); 0.6
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 9
• Chemical Identifiers:
  Formula: C25H30N8O4
  IUPAC Name: N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide
  Canonical SMILES: CN1CCN(C(=O)C1)CC2=C(N=C3C(=C2)CCCN3C(=O)NC4=NC=C(C(=C4)NCCOC)C#N)C=O
  InChI: InChI=1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)
  InChIKey: BHKDKKZMPODMIQ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 118036971
  CAS Number: 1708971-55-4
  TTD ID: D08EQD
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
FGFR4 messenger RNA (FGFR4 mRNA)	TT1KX2S	FGFR4_HUMAN	Antagonist	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)